Administration interval and daptomycin toxicity: A case report of rhabdomyolysis

Journal of Chemotherapy

Volumn 22, Issue 6, 2010, Pages 434-435

  Sbrana, F ^a   di Paolo, A ^b   Pasanisi, E M ^a   Tagliaferri, E ^c   Arvta, C ^a   Puntoni, M ^d   Leonildi, A ^c   Bigazzi, F ^a   Danesi, R ^b   Rovai, D ^a,d   Tascini, C ^c   Menichetti, F ^c  

^a CNR   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

^d INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; DAPTOMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYOGLOBIN; ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC THERAPY; AORTA VALVE REPLACEMENT; ASTHENIA; BACTERIUM ISOLATION; BLOOD CULTURE; BRONCHITIS; CASE REPORT; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPNEA; ENTEROCOCCUS FAECALIS; FEMALE; FEVER; HEART ATRIUM FIBRILLATION; HUMAN; INCUBATION TIME; LEG EDEMA; LETTER; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; RHABDOMYOLYSIS; SEPSIS; TACHYCARDIA; TACHYPNEA; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; GRAM POSITIVE INFECTION; ISOLATION AND PURIFICATION;

AGED; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG ADMINISTRATION SCHEDULE; ENTEROCOCCUS FAECALIS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; RHABDOMYOLYSIS;

EID: 79958281119     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.6.434     Document Type: Letter

References (10)

1. Debono M, Abbott BJ, Molloy RM, Fukuda DS, Hunt AH, Daupert VM et al. Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: the synthesis and evaluation of daptomycin (LY146032). J An-tibiot (Tokyo) 1988; 41(8):1093-105.
2. Cubist Pharmaceuticals. Cubicin (daptomycin for injection) prescribing information. Cubist Pharmaceuticals, Lexinton, Mass 2006.
3. Jeu L, Fung HB. Daptomycin: a cyclic lipopeptide antimicrobial agent. ClinTher. 2004; 26(11): 1728-57.
4. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003; 47(4): 131823.
5. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006; 50(10):3245-9.
6. Figueroa DA, Mangini E, Amodio-Groton M, Vardianos B, Melchert A, Fana C et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009; 49(2):181-3.
7. Cunha BA, Eisenstein LE, Hamid NS. Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: Cure with prolonged/high-dose daptomycin without toxicity. Heart Lung. 2006; 35(3):207-ll.
8. Oleson FB Jr, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother. 2000; 44(11):2948-53.
9. Chakraborty A, Roy S, Loeffler J, Chaves RL. Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. J Antimicrob Chemother. 2009;64(1): 151-8.
10. Center for Drug Evaluation and Research. Approval package for: Application number 21-572. Clinical pharmacology biopharmaceutics review. Available at: http://www.fda.gov/cder/foi/nda/2003/21-572_Cubicin_BioPharmr_Pl.pdf. Accessed October 22, 2004.